Search results for: pediatric

‘Battle for Health Justice’: Dr. Alakija Addresses Global Rheumatology Inequities

Ruth Jessen Hickman, MD | November 10, 2021

On Nov. 3, the inaugural, virtual Global Rheumatology Summit brought together specialists from all over the world to share critical expertise on global health issues related to rheumatology.

Barbara Slusher, MSW, PA-C, Takes the Reins of ARP

Leslie Mertz, PhD | November 8, 2021

Ms. Slusher brings a varied background and many goals to her new role as ARP president, including engaging with volunteers and building connections with all members of healthcare teams.

ACR Convergence 2021: Advocacy Successes & Challenges

Thomas R. Collins | October 25, 2021

The ACR’s advocacy efforts over the past year have helped put critical prior authorization and step therapy legislation in front of Congress. Learn more at ACR Convergence 2021.

FDA Approves Cyltezo, an Interchangeable Biosimilar to Humira

U.S. Food & Drug Administration | October 19, 2021

On Oct. 15, the U.S. Food & Drug Administration (FDA) approved the first interchangeable biosimilar product to treat certain inflammatory diseases. Cyltezo (adalimumab-adbm), originally approved in August 2017, is both biosimilar to and interchangeable with (i.e, may be substituted for) its reference product Humira (adalimumab) for Cyltezo’s approved uses. Cyltezo is the second interchangeable biosimilar…

New ACR Subcommittee Will Advance Diversity, Equity & Inclusion

Susan Bernstein | October 13, 2021

Diversity, equity and inclusion (DEI) are the focus of a new ACR/ARP subcommittee of the Collaborative Initiatives (COIN) Special Committee. The 13-member group will explore strategies to increase diversity in the rheumatology workforce pipeline and reduce implicit bias in such organizational processes as speaker recruitment and abstract review. “There is a new awareness at the…

Regressed germinal center with follicular dendritic cell prominence (star), onion-skinning (blue arrowhead) and increased vascularity (orange arrows) are seen.

Case Report: Is It Castleman Disease, or Castleman-Like?

Philip Chu, MD, RhMSUS, Mithu Maheswaranathan, MD, Jadee L. Neff, MD, PhD, & Rebecca E. Sadun, MD, PhD | October 13, 2021

The difference between Castleman disease and Castleman-like disease may be subtle, but it comes with significant ramifications. Case Presentation This case involves a pregnant 19-year-old woman who presents over multiple hospitalizations with concerns for systemic lupus erythematosus and macrophage activation syndrome. At 36 weeks’ gestation, the patient’s weight had dropped from 215 lbs. to 170…

Healthcare Accessibility for People with Rheumatic Disease in New Haven, CT

Vaidehi R. Chowdhary, MD, & Jane E. Dee, BA, MALS | October 13, 2021

The COVID-19 pandemic exacerbated wide disparities that exist in the U.S. healthcare system. During the pandemic, the clinical practice in the Section of Rheumatology, Allergy & Immunology at Yale School of Medicine (YSM), New Haven, Conn., rapidly pivoted from face-to-face visits to telehealth to keep our patients and providers safe. Many patients quickly adapted and…

Lively, Practical Training at Advocacy 101

Leslie Mertz, PhD | October 11, 2021

Amid spirited discussions on drug pricing and insurance challenges, participants got hands-on experience advocating for current bills regulating prior authorization and pharmacy benefit managers.

Rheumatologists Saw a Gain in Compensation in 2020

Carina Stanton | September 22, 2021

Although patient volume temporarily declined due to the COVID-19 pandemic, rheumatologists saw a larger increase in compensation in 2020 than in 2019, according to a recent Medscape survey.